AU2016295949A1 - Nanocapsule for delivery of lipophilic compound and process of preparation thereof - Google Patents
Nanocapsule for delivery of lipophilic compound and process of preparation thereof Download PDFInfo
- Publication number
- AU2016295949A1 AU2016295949A1 AU2016295949A AU2016295949A AU2016295949A1 AU 2016295949 A1 AU2016295949 A1 AU 2016295949A1 AU 2016295949 A AU2016295949 A AU 2016295949A AU 2016295949 A AU2016295949 A AU 2016295949A AU 2016295949 A1 AU2016295949 A1 AU 2016295949A1
- Authority
- AU
- Australia
- Prior art keywords
- capsules
- templated
- oleic acid
- pct
- cores
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002088 nanocapsule Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title claims description 34
- 230000008569 process Effects 0.000 title claims description 18
- 150000002634 lipophilic molecules Chemical class 0.000 title claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 37
- 239000005017 polysaccharide Substances 0.000 claims abstract description 37
- 150000004676 glycans Chemical class 0.000 claims abstract description 36
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 5
- 230000007774 longterm Effects 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 154
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 65
- 229920001661 Chitosan Polymers 0.000 claims description 47
- 239000011162 core material Substances 0.000 claims description 33
- 235000019198 oils Nutrition 0.000 claims description 32
- 229920002674 hyaluronan Polymers 0.000 claims description 31
- 229960003160 hyaluronic acid Drugs 0.000 claims description 31
- 239000003921 oil Substances 0.000 claims description 31
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 30
- 238000009826 distribution Methods 0.000 claims description 28
- -1 polyornityne Polymers 0.000 claims description 26
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 25
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 25
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 25
- 239000005642 Oleic acid Substances 0.000 claims description 25
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 25
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 25
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 21
- 229920000867 polyelectrolyte Polymers 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 13
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 229920002971 Heparan sulfate Polymers 0.000 claims description 11
- 239000000944 linseed oil Substances 0.000 claims description 10
- 235000021388 linseed oil Nutrition 0.000 claims description 10
- 238000000527 sonication Methods 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 239000010478 argan oil Substances 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 7
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 7
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical class O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 229920000288 Keratan sulfate Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 6
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical group CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 5
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 5
- 229940051593 dermatan sulfate Drugs 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000020477 pH reduction Effects 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 claims description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 4
- 229920002643 polyglutamic acid Polymers 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 229920000856 Amylose Polymers 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- 238000000942 confocal micrograph Methods 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 claims description 3
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 3
- 229960002796 polystyrene sulfonate Drugs 0.000 claims description 3
- 239000011970 polystyrene sulfonate Substances 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 2
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000001878 scanning electron micrograph Methods 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims 3
- 239000012071 phase Substances 0.000 claims 3
- 239000000284 extract Substances 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 239000010685 fatty oil Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract description 6
- 239000007864 aqueous solution Substances 0.000 description 16
- 230000006641 stabilisation Effects 0.000 description 16
- 238000011105 stabilization Methods 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000002296 dynamic light scattering Methods 0.000 description 14
- 239000007908 nanoemulsion Substances 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000975 dye Substances 0.000 description 8
- 125000000129 anionic group Chemical group 0.000 description 6
- 230000001687 destabilization Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000000733 zeta-potential measurement Methods 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical group CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 3
- 125000003010 ionic group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical group CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical group CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 229910052736 halogen Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical group CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021240279A AU2021240279A1 (en) | 2015-07-17 | 2021-09-30 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
| AU2024201288A AU2024201288A1 (en) | 2015-07-17 | 2024-02-27 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.413155 | 2015-07-17 | ||
| PL413155A PL229276B1 (pl) | 2015-07-17 | 2015-07-17 | Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania |
| PCT/PL2016/050032 WO2017014655A1 (en) | 2015-07-17 | 2016-07-12 | Nanocapsule for delivery of lipophilic compound and process of preparation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021240279A Division AU2021240279A1 (en) | 2015-07-17 | 2021-09-30 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016295949A1 true AU2016295949A1 (en) | 2018-02-01 |
Family
ID=56801756
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016295949A Abandoned AU2016295949A1 (en) | 2015-07-17 | 2016-07-12 | Nanocapsule for delivery of lipophilic compound and process of preparation thereof |
| AU2021240279A Abandoned AU2021240279A1 (en) | 2015-07-17 | 2021-09-30 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
| AU2024201288A Pending AU2024201288A1 (en) | 2015-07-17 | 2024-02-27 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021240279A Abandoned AU2021240279A1 (en) | 2015-07-17 | 2021-09-30 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
| AU2024201288A Pending AU2024201288A1 (en) | 2015-07-17 | 2024-02-27 | Nanocapsule for Delivery of Lipophilic Compound and Process of Preparation Thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10821083B2 (enExample) |
| EP (1) | EP3324939A1 (enExample) |
| JP (1) | JP6971217B2 (enExample) |
| KR (1) | KR20180025318A (enExample) |
| CN (1) | CN107847441B (enExample) |
| AU (3) | AU2016295949A1 (enExample) |
| CA (1) | CA2992705A1 (enExample) |
| MX (1) | MX387005B (enExample) |
| PL (1) | PL229276B1 (enExample) |
| RU (1) | RU2723374C1 (enExample) |
| WO (1) | WO2017014655A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018176047A (ja) * | 2017-04-10 | 2018-11-15 | パナソニックＩｐマネジメント株式会社 | マイクロカプセル及びマイクロカプセルの製造方法、並びに、化粧料及び化粧料の製造方法 |
| CN109535430A (zh) * | 2017-09-22 | 2019-03-29 | 天津大学 | 一种油酰化壳寡糖胍接枝聚乙烯亚胺的两亲性衍生物及其制备方法 |
| ES2711669A1 (es) * | 2017-11-02 | 2019-05-06 | Univ Santiago Compostela | Sistemas de liberacion de farmacos de acido polisialico y metodos |
| CN108246215B (zh) * | 2017-12-21 | 2020-06-30 | 四川大学 | 一种超薄壁壳聚糖微囊及其制备方法 |
| PL240632B1 (pl) * | 2018-04-06 | 2022-05-09 | Univ Jagiellonski | Zastosowanie nanokapsuły z ciekłym rdzeniem olejowym w terapii przeciwnowotworowej |
| CN108739807B (zh) * | 2018-06-21 | 2021-07-13 | 中国热带农业科学院农产品加工研究所 | 植物油酸-壳聚糖基纳米微胶囊农药、其制备方法及其应用 |
| CN112888428A (zh) * | 2018-08-17 | 2021-06-01 | 克里兹托夫·斯梅拉 | 包封亲脂和亲水性化合物的纳米胶囊包纳米胶囊型的多隔室体系及相关生产方法 |
| CN109925983B (zh) * | 2019-03-08 | 2021-12-28 | 紫罗兰家纺科技股份有限公司 | 基于乳木果油的双层微胶囊及其整理到纺织面料中的方法 |
| CN111920782B (zh) * | 2019-05-13 | 2025-11-18 | 中国医学科学院药物研究所 | 复合脂质纳米囊组合物及其制备方法和应用 |
| CN112300767B (zh) * | 2020-09-22 | 2022-04-05 | 山东大学 | 一种绿色靶向微胶囊及制备体系、制备方法和应用 |
| EP4321175B1 (en) | 2022-08-11 | 2025-07-16 | CHDE Polska S.A. | Magnetic polymer nanocapsules suitable for use in therapy, especially anti-cancer ones |
| PL446441A1 (pl) * | 2023-10-20 | 2025-04-22 | Chde Polska Spółka Akcyjna | 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US20060063676A1 (en) | 2004-09-17 | 2006-03-23 | Brigance Mickey R | Method for enhancing deposition of an agrochemical |
| CA2618974C (en) | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
| EP2026771B1 (en) * | 2006-01-23 | 2009-10-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Microspheres comprising nanocapsules containing a lipophilic drug |
| ATE515260T1 (de) * | 2006-03-13 | 2011-07-15 | Advanced In Vitro Cell Technologies S L | Stabile nanokapselsysteme für die verabreichung von wirkstoffen |
| EP2266546A1 (en) | 2009-06-08 | 2010-12-29 | Advancell Advanced in Vitro Cell Technologies,S.A. | Process for the preparation of colloidal systems for the delivery of active compounds |
| CN102161729B (zh) * | 2011-02-25 | 2013-01-16 | 上海交通大学 | 水溶性多糖与疏水性单体形成纳米粒子的制备方法 |
| ES2366255B2 (es) | 2011-06-27 | 2012-08-08 | Universidade De Santiago De Compostela | Nanocomposiciones sacarídicas para la liberación de vacunas. |
| RU2494728C1 (ru) | 2012-08-16 | 2013-10-10 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") | Наноэмульсия, содержащая биологически активное вещество |
| CZ304654B6 (cs) * | 2012-11-27 | 2014-08-20 | Contipro Biotech S.R.O. | Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití |
| JP2016531112A (ja) | 2013-07-25 | 2016-10-06 | ネムコア メディカル イノベーションズ インコーポレイテッド | 疎水性白金誘導体のナノエマルジョン |
-
2015
- 2015-07-17 PL PL413155A patent/PL229276B1/pl unknown
-
2016
- 2016-07-12 JP JP2018501907A patent/JP6971217B2/ja active Active
- 2016-07-12 AU AU2016295949A patent/AU2016295949A1/en not_active Abandoned
- 2016-07-12 CA CA2992705A patent/CA2992705A1/en active Pending
- 2016-07-12 EP EP16757368.2A patent/EP3324939A1/en active Pending
- 2016-07-12 KR KR1020187004688A patent/KR20180025318A/ko not_active Ceased
- 2016-07-12 WO PCT/PL2016/050032 patent/WO2017014655A1/en not_active Ceased
- 2016-07-12 US US15/743,728 patent/US10821083B2/en active Active
- 2016-07-12 RU RU2018103323A patent/RU2723374C1/ru active
- 2016-07-12 MX MX2018000637A patent/MX387005B/es unknown
- 2016-07-12 CN CN201680042159.7A patent/CN107847441B/zh active Active
-
2020
- 2020-07-17 US US16/932,369 patent/US20200345651A1/en not_active Abandoned
-
2021
- 2021-09-30 AU AU2021240279A patent/AU2021240279A1/en not_active Abandoned
-
2024
- 2024-02-27 AU AU2024201288A patent/AU2024201288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017014655A1 (en) | 2017-01-26 |
| MX2018000637A (es) | 2018-09-06 |
| CN107847441A (zh) | 2018-03-27 |
| PL413155A1 (pl) | 2017-01-30 |
| RU2723374C1 (ru) | 2020-06-10 |
| AU2024201288A1 (en) | 2024-03-14 |
| US20180200197A1 (en) | 2018-07-19 |
| EP3324939A1 (en) | 2018-05-30 |
| US20200345651A1 (en) | 2020-11-05 |
| MX387005B (es) | 2025-03-12 |
| PL229276B1 (pl) | 2018-06-29 |
| CA2992705A1 (en) | 2017-01-26 |
| CN107847441B (zh) | 2021-08-13 |
| AU2021240279A1 (en) | 2021-10-28 |
| US10821083B2 (en) | 2020-11-03 |
| JP2018523642A (ja) | 2018-08-23 |
| KR20180025318A (ko) | 2018-03-08 |
| HK1251154A1 (zh) | 2019-01-25 |
| JP6971217B2 (ja) | 2021-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200345651A1 (en) | Nanocapsule for delivery of lipophilic compound and process of preparation thereof | |
| Mehandole et al. | Core–shell type lipidic and polymeric nanocapsules: the transformative multifaceted delivery systems | |
| Lai et al. | Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate | |
| Riley et al. | Colloidal stability and drug incorporation aspects of micellar-like PLA–PEG nanoparticles | |
| Liu et al. | Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method | |
| AlQahtani et al. | Improved pharmacokinetic and biodistribution of 5-fluorouracil loaded biomimetic nanoerythrocytes decorated nanocarriers for liver cancer treatment | |
| US8518450B2 (en) | Nanoparticle carriers for drug administration and process for producing same | |
| Corrias et al. | New methods for lipid nanoparticles preparation | |
| Waglewska et al. | Self-assembled bilosomes with stimuli-responsive properties as bioinspired dual-tunable nanoplatform for pH/temperature-triggered release of hybrid cargo | |
| Alibolandi et al. | Smart polymersomes as intelligent nanomedicines in cancer treatment | |
| Obeidat et al. | Chitosan nanoparticles: approaches to preparation, key properties, drug delivery systems, and developments in therapeutic efficacy | |
| Rochín-Wong et al. | Lipid and polymeric Nanocapsules | |
| WO2007078060A1 (en) | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same | |
| Szafraniec et al. | Chitosan-based nanocapsules of core-shell architecture | |
| Chongprakobkit et al. | Oil-in-water emulsions stabilized by sodium phosphorylated chitosan | |
| WO2019159210A1 (en) | Continuous process for coating liposomial vectors with polymer | |
| Froiio et al. | Polymer-based nanocontainers for drug delivery | |
| Benedini et al. | Nanodevices for facing new challenges of medical treatments: stimuli-responsive drug delivery systems | |
| HK1251154B (zh) | 用於递送亲脂性化合物的纳米胶囊及其制备方法 | |
| Kapuścińska et al. | Nanocapsules as carriers of active substances | |
| Conte et al. | Recent advances in “bioartificial polymeric materials” based nanovectors | |
| Aundhia | Nanocapsules | |
| Piegat et al. | Emulsification Parameters Study on Micelles Formation from Hydrophobically Modified Chitosan | |
| Szafraniec-Szczęsny et al. | Chitosan-based nanocapsules of core-shell architecture | |
| Vélaz-Rivas et al. | Lipid and polymeric nanocapsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CHDE POLSKA S.A. Free format text: FORMER APPLICANT(S): UNIWERSYTET JAGIELLONSKI |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |